Treatment for Streptococcus pneumoniae

Outpatient Treatment

• The Infectious Diseases Society of America recommends a macrolide (azithromycin, clarithromycin, or erythromycin) as the first-line choice for previously healthy outpatients without risk factors for resistance 1, 2
• Doxycycline is an alternative option, though with weaker supporting evidence 1
• For patients with comorbidities or risk factors for DRSP, two equally strong first-line options exist: a respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin 750 mg) as monotherapy 1, 4, or a β-lactam plus a macrolide combination 1, 3

Inpatient Non-ICU Treatment

• Two equally effective regimens are recommended: a respiratory fluoroquinolone as monotherapy 1, 2, or a β-lactam plus a macrolide combination 1, 4
• Preferred β-lactams include cefotaxime, ceftriaxone, or ampicillin 1, 2

ICU/Severe Pneumonia Treatment

• Combination therapy is mandatory for severe pneumococcal infections: a β-lactam (cefotaxime, ceftriaxone, or ampicillin-sulbactam) PLUS either azithromycin OR a fluoroquinolone 2, 3, 4

Critical Diagnostic Testing

• For severe CAP/ICU patients, obtain blood cultures 1, urinary antigen tests for S. pneumoniae and Legionella pneumophila 1, and expectorated sputum for culture (or endotracheal aspirate if intubated) 1, 3

Common Pitfalls to Avoid

• Never use macrolide monotherapy in patients with comorbidities or risk factors for DRSP 1
• Avoid switching antibiotic classes if the patient received antimicrobials within the previous 3 months to prevent resistance selection 1
• Do not delay combination therapy in ICU patients—monotherapy is inadequate for severe disease 2
• Do not extend treatment beyond 8-10 days in responding patients without specific indications, as this increases resistance risk without improving outcomes 6